Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 3/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6706470 | 0.95 | MMP1 (0.56) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL2478145 | 0.93 | MMP1 (0.54) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL20515076 | 0.93 | ALDH1A1 (0.56) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL6705193 | 0.92 | MMP1 (0.58) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL25227699 | 0.91 | CES2 (0.52) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL782296 | 0.91 | CES2 (0.52) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL782182 | 0.91 | CES2 (0.52) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL21543936 | 0.91 | ALDH1A1 (0.54) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL3166863 | 0.91 | CES2 (0.52) | ALDH1A1MMP1MMP2MMP3MMP8 | |
| SCHEMBL781502 | 0.91 | CES2 (0.52) | ALDH1A1MMP1MMP2MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118026839-A | Purification method and application of high-purity succinic acid | 安徽丰原发酵技术工程研究有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117897439-A | Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | claimed |
| CN-117897440-A | Method for screening solvent for extraction of polyvinyl chloride, method for recycling waste material, recycled polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | claimed |
| EP-0321556-A4 | USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM | — | 1991-06-12 | — | — | EP | claimed |
| EP-0321556-A1 | USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM | Memorial Hospital for Cancer and Allied Diseases (US) | 1989-06-28 | — | — | EP | claimed |
| WO-1988010114-A1 | USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) | 1988-12-29 | — | — | WO | claimed |
| US-12630731-B2 | Non-aqueous ink composition | DNP FINE CHEMICALS CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260125570-A1 | NONAQUEOUS INK COMPOSITION, RECORDING METHOD, METHOD FOR PRODUCING RECORDED MATERIAL, INK SET, RECORDED MATERIAL, AND INKJET RECORDING APPARATUS | DNP FINE CHEMICALS CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| US-12590216-B2 | Water-based ink and ink set including same | DNP FINE CHEMICALS CO., LTD. (JP) | 2026-03-31 | — | — | US | disclosed |
| US-12522744-B2 | Ink set | DNP FINE CHEMICALS CO., LTD. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20250368766-A1 | RESIN, RESIN DISPERSION, AND RESIN COMPOSITION | DNP FINE CHEMICALS CO., LTD. (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4617333-A1 | NONAQUEOUS INK COMPOSITION, RECORDING METHOD, METHOD FOR PRODUCING RECORDED MATERIAL, INK SET, RECORDED MATERIAL, AND INKJET RECORDING APPARATUS | DNP Fine Chemicals Co., Ltd. (JP) | 2025-09-17 | — | — | EP | disclosed |
| US-12398444-B2 | Diglycolamide derivatives for separation and recovery of rare earth elements from aqueous solutions | UT-BATTELLE, LLC (US) | 2025-08-26 | — | — | US | disclosed |
| EP-0445243-B1 | A METHOD OF PREPARING MONOTHIOPHOSPHORIC ACID BY SULFURIZING A PHOSPHITE IN THE PRESENCE OF AN AMIDE | LUBRIZOL CORP (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0445243-A1 | A METHOD OF PREPARING MONOTHIOPHOSPHORIC ACID BY SULFURIZING A PHOSPHITE IN THE PRESENCE OF AN AMIDE. | LUBRIZOL CORP (US) | 1991-09-11 | — | — | EP | disclosed |
| EP-0321556-A4 | USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM | — | 1991-06-12 | — | — | EP | disclosed |
| WO-1991004979-A1 | A METHOD OF PREPARING MONOTHIOPHOSPHORIC ACID BY SULFURIZING A PHOSPHITE IN THE PRESENCE OF AN AMIDE | THE LUBRIZOL CORPORATION (US) | 1991-04-18 | — | — | WO | disclosed |
| US-4997968-A | Sulfiding phosphonate | THE LUBRIZOL CORPORATION (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0321556-A1 | USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM | Memorial Hospital for Cancer and Allied Diseases (US) | 1989-06-28 | — | — | EP | disclosed |
| WO-1988010114-A1 | USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) | 1988-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630731-B2 | Non-aqueous ink composition | EXOSC10, RPP30, RPS20 | ALDH1A1 1893/4885MMP1 1913/4885MMP2 2771/4885 |
| US-12590216-B2 | Water-based ink and ink set including same | TYR, ITGB3, ARCN1 | ALDH1A1 1130/4885MMP1 213/4885MMP2 2793/4885 |
| US-12398444-B2 | Diglycolamide derivatives for separation and recovery of rare earth elements from aqueous solutions | GNE, GALE, ARGLU1 | ALDH1A1 3536/4885MMP1 2209/4885MMP2 1462/4885 |
| US-20260125570-A1 | NONAQUEOUS INK COMPOSITION, RECORDING METHOD, METHOD FOR PRODUCING RECORDED MATERIAL, INK SET, RECORDED MATERIAL, AND INKJET RECORDING APPARATUS | BMI1, IK, PRDM9 | ALDH1A1 333/4885MMP1 556/4885MMP2 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.